TORONTO, Aug. 26, 2014 /CNW/ - Dr. Barry Sherman, Chairman of the Board of Apotex, is pleased to announce the appointments of Dr. Jeremy B. Desai to President and C.E.O. effective August 1, 2014 and Mr. Jack Kay, the former CEO of Apotex to the position of Vice Chairman of the Board effective the same date.
Born in London, England, Dr. Desai gained a Pharmacy degree in 1981, a PhD in 1985 and an MBA in 1993. He has spent close to 30 years in progressively senior positions in the pharmaceutical industry. Dr. Desai has been at Apotex for the last 11 years in different roles, including EVP and Global Head of R&D and most recently as President and Chief Operating Officer.
He takes over the helm of Apotex at a great time of change in the industry and the healthcare system. This combined with a challenging and evolving global regulatory environment has put the corporate focus on leadership and key strategic planning to succeed.
His objective is to continue to build on the momentum of the last 5 years of building an Apotex "culture of quality" with a commitment to excellence in producing quality affordable pharmaceutical products for patients around the globe.
Apotex is the largest Canadian owned pharmaceutical company with over 5,500 employees in Canada and over 10,000 globally, it has exports to 75 countries with planned R&D expenditures of $2.1 billion over the next 10 years.
SOURCE: Apotex Inc.
For further information: Elie Betito, Director of Public and Government Affairs, Apotex Inc., 200 Barmac Drive, Toronto, Ontario, M9L 2Z7, Office: 416-749-9300 Ext. 7366, Cell: 416-558-5491, Fax: 416-401-3835, Email: firstname.lastname@example.org